{"id":26295,"date":"2024-09-27T10:58:17","date_gmt":"2024-09-27T08:58:17","guid":{"rendered":"https:\/\/idibell.cat\/?p=26295"},"modified":"2024-09-27T10:58:17","modified_gmt":"2024-09-27T08:58:17","slug":"bellvitge-lidera-la-creacio-duna-nova-eina-mes-precisa-per-avaluar-la-toxicitat-neurologica-provocada-per-la-quimioterapia","status":"publish","type":"post","link":"https:\/\/idibell.cat\/2024\/09\/bellvitge-lidera-la-creacio-duna-nova-eina-mes-precisa-per-avaluar-la-toxicitat-neurologica-provocada-per-la-quimioterapia\/","title":{"rendered":"Bellvitge lidera la creaci\u00f3 d\u2019una nova eina m\u00e9s precisa per avaluar la toxicitat neurol\u00f2gica provocada per la quimioter\u00e0pia"},"content":{"rendered":"<p>L&#8217;IDIBELL, l\u2019Hospital Universitari de Bellvitge (HUB) i l&#8217;Institut Catal\u00e0 d&#8217;Oncologia (ICO) han liderat un estudi europeu, publicat a l\u2019<em>European Journal of Neurology<\/em>, que presenta una eina innovadora per avaluar la neuropatia perif\u00e8rica indu\u00efda per la quimioter\u00e0pia (CIPN). Aquest efecte advers el pateixen prop del 40% dels pacients que reben tractaments citost\u00e0tics neurot\u00f2xics, utilitzats en primera l\u00ednia i recaigudes de c\u00e0ncers especialment freq\u00fcents com els de mama, c\u00f2lon, ginecol\u00f2gics, pulm\u00f3 i tumors de cap i coll.<\/p>\n<p>L&#8217;estudi, liderat pel Dr. Jordi Bruna, neur\u00f2leg i l\u00edder del grup de recerca en Neurooncologia de l&#8217;IDIBELL, l\u2019HUB i l\u2019ICO, ha desenvolupat una escala pr\u00e0ctica que integra tant la valoraci\u00f3 m\u00e8dica objectiva com la qualitat de vida reportada pels pacients. Aquesta nova eina permet una avaluaci\u00f3 m\u00e9s completa i precisa de la toxicitat neurol\u00f2gica associada a la quimioter\u00e0pia, fet que resulta clau per prendre decisions terap\u00e8utiques durant els tractaments.<\/p>\n<p>&#8220;El gran avantatge d&#8217;aquest sistema \u00e9s que incorpora la percepci\u00f3 del pacient, un aspecte que fins ara les escales m\u00e8diques no tenien en compte de manera adequada&#8221;, explica el Dr. Bruna. Aquesta integraci\u00f3 \u00e9s essencial per evitar discrep\u00e0ncies entre el que els pacients experimenten i el que les avaluacions m\u00e8diques reflecteixen. Aix\u00f2 pot tenir conseq\u00fc\u00e8ncies importants en la continu\u00eftat o modificaci\u00f3 dels tractaments i, per tant, en les probabilitats d\u2019\u00e8xit d\u2019aquests, i al mateix temps\u00a0 impacta en la qualitat de vida dels supervivents al c\u00e0ncer.<\/p>\n<p>L&#8217;estudi, desenvolupat en col\u00b7laboraci\u00f3 amb diversos centres europeus, subratlla la necessitat d&#8217;una avaluaci\u00f3 m\u00e9s precisa per ajustar els tractaments oncol\u00f2gics i evitar efectes adversos cr\u00f2nics que podrien afectar negativament els pacients que superen un c\u00e0ncer.<\/p>\n<p>&nbsp;<\/p>\n<p><em>L\u2019Institut d\u2019Investigaci\u00f3 Biom\u00e8dica de Bellvitge (IDIBELL) \u00e9s un centre de recerca en biomedicina creat l\u2019any 2004. Est\u00e0 participat per l\u2019Hospital Universitari de Bellvitge i l\u2019Hospital de Viladecans de l\u2019Institut Catal\u00e0 de la Salut, l\u2019Institut Catal\u00e0 d\u2019Oncologia, la Universitat de Barcelona i l\u2019Ajuntament de l\u2019Hospitalet de Llobregat.<\/em><\/p>\n<p><em>L\u2019IDIBELL \u00e9s membre del Campus d\u2019Excel\u00b7l\u00e8ncia Internacional de la Universitat de Barcelona HUBc i forma part de la instituci\u00f3 CERCA de la Generalitat de Catalunya. L\u2019any 2009 es va convertir en un dels cinc primers centres d\u2019investigaci\u00f3 espanyols acreditats com a institut d\u2019investigaci\u00f3 sanit\u00e0ria per l\u2019Instituto de Salud Carlos III. A m\u00e9s, forma part del programa \u201cHR Excellence in Research\u201d de la Uni\u00f3 Europea i \u00e9s membre de EATRIS i REGIC. Des de l\u2019any 2018, l\u2019IDIBELL \u00e9s un Centro Acreditado de la Fundaci\u00f3n Cient\u00edfica AECC (FCAECC).<\/em><\/p>\n","protected":false},"excerpt":{"rendered":"<p>L&#8217;IDIBELL, l\u2019HUB i l\u2019ICO han liderat un estudi europeu que presenta una eina innovadora per avaluar la neuropatia perif\u00e8rica indu\u00efda per la quimioter\u00e0pia (CIPN). El gran avantatge d&#8217;aquest sistema \u00e9s que incorpora la percepci\u00f3 del pacient, un aspecte que fins ara les escales m\u00e8diques no tenien en compte de manera adequada.<\/p>\n","protected":false},"author":8,"featured_media":26297,"comment_status":"closed","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"site-sidebar-layout":"default","site-content-layout":"","ast-site-content-layout":"default","site-content-style":"default","site-sidebar-style":"default","ast-global-header-display":"","ast-banner-title-visibility":"","ast-main-header-display":"","ast-hfb-above-header-display":"","ast-hfb-below-header-display":"","ast-hfb-mobile-header-display":"","site-post-title":"","ast-breadcrumbs-content":"","ast-featured-img":"","footer-sml-layout":"","theme-transparent-header-meta":"default","adv-header-id-meta":"","stick-header-meta":"default","header-above-stick-meta":"","header-main-stick-meta":"","header-below-stick-meta":"","astra-migrate-meta-layouts":"set","ast-page-background-enabled":"default","ast-page-background-meta":{"desktop":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"tablet":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"mobile":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""}},"ast-content-background-meta":{"desktop":{"background-color":"var(--ast-global-color-5)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"tablet":{"background-color":"var(--ast-global-color-5)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"mobile":{"background-color":"var(--ast-global-color-5)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""}},"footnotes":""},"categories":[332,362,447],"tags":[],"class_list":["post-26295","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-cancer","category-neuro-oncologia","category-p-de-mecanismes-molelculars-i-terapia-experimental-en-oncologia-oncobell"],"publishpress_future_action":{"enabled":false,"date":"2025-01-25 06:59:19","action":"change-status","newStatus":"draft","terms":[],"taxonomy":"category"},"publishpress_future_workflow_manual_trigger":{"enabledWorkflows":[]},"_links":{"self":[{"href":"https:\/\/idibell.cat\/wp-json\/wp\/v2\/posts\/26295","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/idibell.cat\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/idibell.cat\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/idibell.cat\/wp-json\/wp\/v2\/users\/8"}],"replies":[{"embeddable":true,"href":"https:\/\/idibell.cat\/wp-json\/wp\/v2\/comments?post=26295"}],"version-history":[{"count":1,"href":"https:\/\/idibell.cat\/wp-json\/wp\/v2\/posts\/26295\/revisions"}],"predecessor-version":[{"id":26298,"href":"https:\/\/idibell.cat\/wp-json\/wp\/v2\/posts\/26295\/revisions\/26298"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/idibell.cat\/wp-json\/wp\/v2\/media\/26297"}],"wp:attachment":[{"href":"https:\/\/idibell.cat\/wp-json\/wp\/v2\/media?parent=26295"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/idibell.cat\/wp-json\/wp\/v2\/categories?post=26295"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/idibell.cat\/wp-json\/wp\/v2\/tags?post=26295"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}